Objects
Denham, James W., Steigler, Allison, Gleeson, Paul S., Greer, Peter B., D'Este, Catherine, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David. Elsevier; 2008. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial.
Capp, Anne, Inostroza-Ponta, Mario, Atkinson, Chris, North, John, Poulsen, Michael, Spry, Nigel A., Tai, Keen-Hun, Wynne, Chris, Duchesne, Gillian, Steigler, Allison, Denham, James W., Bill, Dana, Moscato, Pablo, Lai, Chi, Christie, David, Lamb, David, Turner, Sandra, Joseph, David, Matthews, John. Elsevier; 2009. Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial.
Denham, James W., Wilcox, Chantelle, Gogna, Nirdosh Kumar, Kenny, Lizbeth, Duchesne, Gillian, Delahunt, Brett, McElduff, Patrick, Joseph, David, Spry, Nigel A., Lamb, David S., Tai, Keen-Hun, Matthews, John, Atkinson, Chris, Turner, Sandra, Christie, David. Lancet Publishing Group; 2012. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham, James W., Kumar, Mahesh, Turner, Sandra, Greer, Peter B., D'Este, Catherine, Steigler, Allison, Gleeson, Paul S., Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David. Elsevier; 2009. Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer.
Delahunt, Brett, Murray, Judith D., Steigler, Allison, Atkinson, Chris, Christie, David, Duchesne, Gillian, Egevad, Lars, Joseph, David, Matthews, John, Oldmeadow, Christopher, Samaratunga, Hemamali, Spry, Nigel A., Srigley, John R., Hondermarck, Hubert, Denham, James W.. Wiley-Blackwell; 2020. Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial.
Lamb, David, Joesph, David, Turner, Sandra, Diamond, Terry, Steigler, Allison, Attia, John, Delahunt, Brett, Haworth, Annette, Denham, Jim, Duchesne, Gillian, Atkinson, Chris, Kenny, Lizbeth, Gogna, Kumar, Matthews, John, Spry, Nigel, Tai, Keen-Hun. A randomised trial investigating the effect on biochemical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate.
Sridharan, Swetha, Steigler, Allison, Attia, John, Holliday, Elizabeth G., Denham, James W., Spry, Nigel A., Joseph, David, Lamb, David S., Matthews, John H., Atkinson, Chris, Tai, Keen-Hun, Duchesne, Gillian, Christie, David. Elsevier; 2016. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial.
Denham, James W., Steigler, Allison, Wynne, Chris, Lamb, David S., Tai, Keen-Hun, Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Turner, Sandra, North, John, Christie, David. Elsevier Ireland; 2013. Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer.
Denham, James W., Steigler, Allison, Tai, Keen-Hun, Wynne, Chris, D'Este, Catherine, Lamb, David S., Joseph, David, Turner, Sandra, Matthews, John, Atkinson, Chris, North, John, Christie, David, Spry, Nigel A.. The Lancet Publishing Group; 2011. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham, James W., Joseph, David, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Matthews, John, Atkinson, Chris, Tai, Keen-Hun, Christie, David, Kenny, Lizbeth, Turner, Sandra, Gogna, Nirdosh Kumar, Diamond, Terry, Delahunt, Brett, Oldmeadow, Chris, Attia, John, Steigler, Allison. The Lancet Publishing Group; 2019. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Lamb, David S., Denham, James W., D'Este, Catherine, Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Duchesne, Gillian, Ebert, Martin, Steigler, Allison, Delahunt, Brett. Elsevier; 2011. A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial.
Denham, James W., Lamb, David S., Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Duchesne, Gillian, Ebert, Martin, Steigler, Allison, D'Este, Catherine. Elsevier; 2009. PSA response signatures: a powerful new prognostic indicator after radiation for prostate cancer?.
Denham, James W., Wilcox, Chantelle, Gogna, Nirdosh Kumar, Ebert, Martin, Delahunt, Brett, McElduff, Patrick, Joseph, David, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Atkinson, Chris, Matthews, John, Turner, Sandra, Kenny, Lizabeth, Tai, Keen-Hun. Elsevier Ireland; 2012. Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer.
Denham, James W., Steigler, Allison, Tai, Keen-Hun, Gogna, Nirdosh Kumar, Gill, Suki, Tan, Hendrick, Kearvell, Rachel, Murray, Judy, Ebert, Martin, Haworth, Annette, Kennedy, Angel, Delahunt, Brett, Joseph, David, Oldmeadow, Christopher, Holliday, Elizabeth G., Attia, John, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Atkinson, Chris, Matthews, John, Turner, Sandra, Kenny, Lizbeth. Elsevier; 2015. Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial.
Denham, James W., Steigler, Allison, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Tai, Keen-Hun, Spry, Nigel A., Gleeson, Paul S., D'Este, Catherine. John Wiley & Sons; 2009. Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?.
Denham, James W., Steigler, Allison, Gleeson, Paul S., D'Este, Catherine, Kumar, Mahesh, Lamb, David S., Joseph, David, Spry, Nigel A., Tai, Keen-Hun, Atkinson, Chris, Turner, Sandra, Greer, Peter B.. Elsevier; 2009. Measuring time to biochemical failure in the Trog 96.01 trial: when should the clock start ticking?.
Steigler, Allison, Denham, James W., Tai, Keen-Hun, Wynne, Chris, Lamb, David S., Spry, Nigel A., Joseph, David, Matthews, John, Atkinson, Chris, Turner, Sandra, North, John, Christie, David. Hindawi Publishing; 2012. Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: data from the TROG 96.01 trial.
Joseph, David, Denham, James W., Turner, Sandra, Kenny, Lizbeth, Christie, David, Tai, Keen-Hun, Gogna, NirdoshK, Kearvell, Rachel, Murray, Judy, Ebert, Martin A., Haworth, Annette, Delahunt, Brett, Steigler, Allison, Oldmeadow, Christopher, Attia, John, Lamb, David S., Spry, Nigel A., Stanley, John, Shannon, Tom, Duchesne, Gillian, Atkinson, Chris, Matthews, John H. L.. Elsevier; 2020. Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial.